[
  {
    "ts": null,
    "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2025 Update",
    "summary": "See an update on Prem Watsa's latest 13F portfolio moves, find out his top stock picks, global strategy, and key insights for focused, long-term investing.",
    "url": "https://finnhub.io/api/news?id=628bb2894b5e7b55dcceee727c68da960b38694f77e54a37375520f34a37c29b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757451534,
      "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2025 Update",
      "id": 136680992,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1264256639/image_1264256639.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "See an update on Prem Watsa's latest 13F portfolio moves, find out his top stock picks, global strategy, and key insights for focused, long-term investing.",
      "url": "https://finnhub.io/api/news?id=628bb2894b5e7b55dcceee727c68da960b38694f77e54a37375520f34a37c29b"
    }
  },
  {
    "ts": null,
    "headline": "SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study",
    "summary": "Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.",
    "url": "https://finnhub.io/api/news?id=fffd6928c554d8bcd2be2755cb29885056432248483ff93cfba371983421670f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757441820,
      "headline": "SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study",
      "id": 136688959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.",
      "url": "https://finnhub.io/api/news?id=fffd6928c554d8bcd2be2755cb29885056432248483ff93cfba371983421670f"
    }
  },
  {
    "ts": null,
    "headline": "Will LLY's Oncology Portfolio Provide Key Diversification Benefits?",
    "summary": "Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.",
    "url": "https://finnhub.io/api/news?id=1c5055be8f07e03450784c1fc367be823dcd3887dc84bcce36a14fc76eb64cf6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757434860,
      "headline": "Will LLY's Oncology Portfolio Provide Key Diversification Benefits?",
      "id": 136688960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.",
      "url": "https://finnhub.io/api/news?id=1c5055be8f07e03450784c1fc367be823dcd3887dc84bcce36a14fc76eb64cf6"
    }
  },
  {
    "ts": null,
    "headline": "Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?",
    "summary": "MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.",
    "url": "https://finnhub.io/api/news?id=d9e62dcde8b69fc30e781157f6019c250d7b468dbca567808a48a9faf9da0b7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757425800,
      "headline": "Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?",
      "id": 136688961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.",
      "url": "https://finnhub.io/api/news?id=d9e62dcde8b69fc30e781157f6019c250d7b468dbca567808a48a9faf9da0b7d"
    }
  }
]